CSAClinical-Stage Asset Intelligence
Catalyst calendar Get the data
Home / Novartis AG (NVS) / tisagenlecleucel
Forward catalyst · NVS

tisagenlecleucel

Sponsor Novartis AG · listed as NVS

READOUT Phase 3 Confidence: medium Source: clinicaltrials

tisagenlecleucel is a clinical-stage drug asset sponsored by Novartis AG, listed as NVS. CSA tracks 1 forward catalyst for it — the nearest is a readout expected Mar 31, 2027 (day precision, medium confidence), tied to trial NCT04094311. The asset is in Phase 3 and currently recruiting, studied in B-cell Acute Lymphoblastic Leukemia. It appears across 2 tracked trials in the CSA sample.

Next catalyst

Event typeREADOUT
Expected date2027-03-31
As disclosedMar 31, 2027
Date precisionday
Confidencemedium
Verify at source →

Trial & sponsor

Trial (NCT)NCT04094311
PhasePHASE3
StatusRECRUITING
Lead sponsorNovartis Pharmaceuticals
Listed asNVS
Condition(s)B-cell Acute Lymphoblastic Leukemia; Diffuse Large B-cell Lymphoma
!

Data, not investment advice. CSA is information, not a recommendation to buy, sell or hold any security. Estimated catalyst dates routinely slip and are graded by confidence — verify against the source link before acting.

This is one row of the free CSA sample. The full snapshot carries 2,103 forward catalysts across 139 listed sponsors.

Get the full dataset — $499 →   More NVS catalysts